

GREGORY Q. MARSELLA, M.D., P.A.
Atrium Financial Center
1515 North Federal Highway
Suite 105
Boca Raton, Florida 33432
561-394-2532

CAREER

March 1997- Present Principal Investigator and Founder, Gregory Q. Marsella, M.D., P.A.
Boca Raton, Florida
Contract Clinical Trials and Grant-Based Medical Research

April 1992-Present Private Practice of Adult and Adolescent Psychiatry/Psychopharmacology
Boca Raton, Florida

November 2009-Present rTMS Therapy
Boca Raton, Florida
Repetitive Transcranial Magnetic Stimulation

July 1987-April 1992 Delray Medical Center
Delray Beach, Florida
Director of Adolescent Psychiatric Treatment Services
Medical Director of Adolescent Psychiatric Inpatient Unit

EDUCATION

1984-1987 New York Hospital-Cornell Medical Center-Westchester
Psychiatry Residency

1983-1984 New York Hospital-Cornell Medical Center-Payne Whitney;
New York Hospital-Cornell Medical Center-Westchester;
Memorial Sloan-Kettering Cancer Center;
Laguardia Hospital-Forest Hills
Internship

1978-1983 University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Doctor of Medicine Degree

1971-1976 Harvard University
Cambridge, Massachusetts
B.A. Degree Cum Laude in English Literature; Thesis Rank: Magna Cum Laude

PSYCHIATRIC EDUCATION

Medical School

- 8 week clerkship in Adult Psychiatry, Hospital of the University of Pennsylvania (HUP)
- 8 week externship in Advanced Inpatient Psychiatry, HUP
- 4 week clerkship in Child Psychiatry, Philadelphia Child Guidance Clinic, HUP
- 4 week Specialized Study in Psychiatry (Psychoanalysis), HUP

Internship

- 2 months Neurology, Memorial Sloan-Kettering Cancer Center
- 4 months Medicine, Laguardia Hospital-Forest Hills
- 2 months Geriatric Psychiatry, New York Hospital-Cornell Medical Center
- 2 months Drug and Alcohol Rehabilitation, New York Hospital-Cornell Medical Center

-2 months Psychiatric Evaluation Service, New York Hospital-Cornell Medical Center
Psychiatry Residency
-6 months Diagnostic Evaluation Services, New York Hospital-Cornell Medical Center
-6 months Psychiatric Inpatient Services, New York Hospital-Cornell Medical Center
-12 months Adult Outpatient Psychiatry, New York Hospital-Cornell Medical Center
-3 months Child and Adolescent Psychiatry, New York Hospital-Cornell Medical Center
-6 months Adolescent Inpatient Services, New York Hospital-Cornell Medical Center
-3 months Consultation-Liaison Services, New York Hospital-Cornell Medical Center

MEMBERSHIPS

American Medical Association
American Psychiatric Association
American Academy of Child and Adolescent Psychiatry

LICENSURE

Florida Medical License: ME 0051261
New York Medical License: 161138-1
DEA: BM 1056731

BOARD CERTIFICATION

Diplomate, American Board of Psychiatry and Neurology, Certificate 42544
Diplomate, National Board of Medical Examiners

HOSPITAL PRIVILEGES

West Boca Medical Center, Boca Raton, Florida

COVERAGE

24 Hour Coverage by Voicemail/Emergency Beeper
Vacation/Out-Of-Town Same-Office Coverage by Colleagues

PRACTICE DESCRIPTION

General Adult and Adolescent Psychiatric Consultations
Adult and Adolescent Psychopharmacology
Repetitive Transcranial Magnetic Stimulation (rTMS)
Contract Clinical Trials and Grant-Based Medical Research

BRIEF CLINICAL RESEARCH BIOGRAPHY

Gregory Marsella is the founder of Gregory Q. Marsella, M.D., P.A., a small, independent clinical research company that does grant-based medical research and also offers local, contract research services to Fortune 500 pharmaceutical companies, biotechnology companies, and national CRO's. Dr. Marsella is a physician by training and a board-certified psychiatrist who received his B.A. at Harvard, his M.D. at the University of Pennsylvania, and his residency training in psychiatry at New York Hospital-Cornell Medical Center. In addition to its other missions Gregory Q. Marsella, M.D., P.A. is a medical research network furnishing study-procural, patient-recruitment, site-management, and research administrative services for its participating practices in Florida. Dr. Marsella has been a site investigator for Phase II, III, and IV multicenter, nationwide clinical trials, and has also authored and implemented grant-based medical research studies in child and adult psychopharmacology, neurology, epilepsy medicine, pain-management, and rheumatology.

RECENT PHASE II, III, AND IV MULTICENTER CLINICAL TRIALS, AND INVESTIGATOR-AUTHORED, GRANT-SUBSIDIZED RESEARCH PROTOCOLS, IN WHICH DR. MARSELLA WAS A PRINCIPAL INVESTIGATOR

1. "Nefazodone in the Treatment of Patients with Chronic Pain." (authored by Dr. Marsella, subsidized by a grant from Bristol-Myers Squibb)
2. "A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of the Efficacy of Sertraline in the Treatment of Dysthymia." (authored by Dr. Marsella, subsidized by a grant from Pfizer)
3. "Nefazodone in the Treatment of Agitated Geriatric Patients." (authored by Dr. Marsella, subsidized by a grant from Bristol-Myers Squibb)
4. "A Placebo-Controlled Study of Olanzapine Monotherapy in the Treatment of Bipolar I Depression." (sponsored by Eli Lilly)
5. "An Open-Label Combination of Olanzapine and Fluoxetine in Major Depressive Disorder." (sponsored by Eli Lilly)
6. "A Twelve-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD)." (sponsored by GlaxoSmithKline)
7. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Doses of Aripiprazole in the Treatment of Hospitalized Patients with Acute Mania." (sponsored by Bristol-Myers Squibb)
8. "An Open-Label Study of Tolerability, Clinical Response, and Satisfaction in Adult Bipolar I Subjects Optimizing Initiation of Therapy Using Administration of Dermatological Precautions and Lamictal Titration Packs." (sponsored by GlaxoSmithKline)
9. "A Multi-Center, Open-Label, Long-Term Study of the Safety, Tolerability and Efficacy of Aripiprazole in the Maintenance Treatment of Patients with Bipolar Disorders." (sponsored by Bristol-Myers Squibb)
10. "An Open-Label Evaluation of Lamotrigine Versus Carbamazepine, Phenytoin, and Divalproex Sodium as Monotherapy Treatment for Epilepsy Patients Who Have Failed a Previous Course of Anti-Epileptic Drug Therapy." (sponsored by GlaxoSmithKline)
11. "Open-Label Use of Keppra (Levetiracetam) in the Treatment of Agitated States in Patients Over 50." (authored by Dr. Marsella, subsidized by a grant from UCB Pharma)
12. "Lilly's Emotional and Physical Symptoms of Depression Study." (sponsored by Eli Lilly)
13. "A Multicenter, Randomized, Open-Label, Parallel-Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment with Niravam and an SSRI or SNRI to Treatment with an SSRI or SNRI Alone in Subjects with Generalized Anxiety Disorder or Panic Disorder." (sponsored by Schwarz Pharma)
14. "A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With a Diagnosis of Bipolar I Depression." (sponsored by Pfizer)
15. "An International, Multicenter, Large Simple Trial (LST) to Compare the Cardiovascular Safety of Ziprasidone and Olanzapine in Patients With Schizophrenia." (sponsored by Pfizer)
16. "A Multicenter, Double-Blind Study on the Efficacy and Safety of Aripiprazole in Combination with Lamotrigine in the Long-Term Maintenance Treatment of Patients with Bipolar I Disorder with a Recent Manic or Mixed Episode." (sponsored by Bristol-Myers Squibb)
17. "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder." (sponsored by Bristol-Myers Squibb)
18. "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study with Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents with Autistic Disorder." (sponsored by Bristol-Myers Squibb)
19. "A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder." (sponsored by Bristol-Myers Squibb)
20. "A Randomized, Multi-Center, Double-Blind, Parallel-Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients." (sponsored by Solvay Pharmaceuticals)
21. "A Multi-Center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the

- Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder.” (sponsored by Solvay Pharmaceuticals)
22. “Risperidone in the Treatment of Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety Followed by an Open-Label Extension Study of Safety.” (sponsored by Johnson & Johnson)
 23. “A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of AVE1625 5, 10, and 30 mg and Placebo on top of an Established Treatment Regimen of Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia.” (sponsored by Sanofi-Aventis)
 24. “Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents.” (sponsored by Lexicor Medical Technology)
 25. “A Phase Two, Six-Week, Double-Blind, Placebo-Controlled, Multicenter Trial of Varenicline Tartrate (CP-526,555) for Cognitive Impairment in Subjects with Schizophrenia.” (sponsored by Pfizer)
 26. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain.” (sponsored by Wyeth)
 27. “A Multicenter, Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain.” (sponsored by Wyeth)
 28. “An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Extended-release in Children and Adolescent Subjects with Bipolar Depression.” (sponsored by AstraZeneca)
 29. “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study (804P301) to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Two Concomitant Antiepileptic Medications.” (sponsored by Supernus)
 30. “A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Two Concomitant Antiepileptic Medications.” (sponsored by Supernus)
 31. “A Six-Month, Multi-Center, Placebo-Controlled, Chronic Migraine Treatment Trial with combination Topamax (50-100mg) and either Propranolol or Placebo.” (sponsored by the NIH: National Institute of Neurological Disorders and Stroke/National Institutes of Health)

REFERENCES

Furnished upon request

(Version Date 01/21/2011)